根据对孕龄为 20 - < 36 周、17-34 周和 > 28 周且接种过 1 剂(0.5 mL)三价疫苗(Vaxigrip Tetra)的母亲的研究,在孕龄为 20 至 32 周的孕妇中,疫苗效力最好为 1 剂(0.5 mL),而通过母体抗体被动转移给新生儿而产生的效力会降低,直到婴儿不到 6 个月大。 4.定期利益风险评估报告数据显示对孕妇用药的安全性。 Vaxigrip Tetra SH/NH 的效益风险评估是一种具有灭活疫苗平台的流感疫苗。该疫苗此前已被批准用于儿童和成人,并被批准用于孕妇的附加适应症和用法用量,以及为从出生到 6 个月以下的婴儿提供针对流感的被动保护。根据临床研究结果获得的有效性和安全性数据,Vaxigrip Tetra SH/NH疫苗具有以下有益作用、不良作用、不确定性和局限性:
在临床研究中参与合并症的受试者中观察到的Vaxigriptetra的安全性与在整体人群中观察到的受试者没有差异。此外,在肾移植患者中对Vaxigrip进行的研究,哮喘患者在这些人群中Vaxigrip的安全性方面没有显着差异。在南非和马里孕妇进行的临床研究中使用Vaxigrip进行的孕妇(请参阅第4.6和5.1节),在疫苗给药后7天内报道的本地和全身性征求反应的频率与vaxigrip进行临床研究期间成人人群报道的疫苗一致。 在南非的研究中,Vaxigrip组的局部反应比在HIV阴性和HIV阳性队列中的安慰剂组中更频繁。 在两个队列中,Vaxigrip和安慰剂组之间的征求反应没有其他显着差异。 In one clinical study conducted in pregnant women in Finland with VaxigripTetra (see sections 4.6 and 5.1), frequencies of local and systemic solicited reactions reported within 7 days following administration of VaxigripTetra were consistent with those reported for the adult population (with the exception of pregnant women) during clinical studies conducted with VaxigripTetra even though higher for some adverse reactions (injection site pain, malaise, shivering, headache,肌痛)。使用Vaxigrip进行的孕妇(请参阅第4.6和5.1节),在疫苗给药后7天内报道的本地和全身性征求反应的频率与vaxigrip进行临床研究期间成人人群报道的疫苗一致。在南非的研究中,Vaxigrip组的局部反应比在HIV阴性和HIV阳性队列中的安慰剂组中更频繁。 在两个队列中,Vaxigrip和安慰剂组之间的征求反应没有其他显着差异。 In one clinical study conducted in pregnant women in Finland with VaxigripTetra (see sections 4.6 and 5.1), frequencies of local and systemic solicited reactions reported within 7 days following administration of VaxigripTetra were consistent with those reported for the adult population (with the exception of pregnant women) during clinical studies conducted with VaxigripTetra even though higher for some adverse reactions (injection site pain, malaise, shivering, headache,肌痛)。在南非的研究中,Vaxigrip组的局部反应比在HIV阴性和HIV阳性队列中的安慰剂组中更频繁。在两个队列中,Vaxigrip和安慰剂组之间的征求反应没有其他显着差异。In one clinical study conducted in pregnant women in Finland with VaxigripTetra (see sections 4.6 and 5.1), frequencies of local and systemic solicited reactions reported within 7 days following administration of VaxigripTetra were consistent with those reported for the adult population (with the exception of pregnant women) during clinical studies conducted with VaxigripTetra even though higher for some adverse reactions (injection site pain, malaise, shivering, headache,肌痛)。
